For the third quarter of the fiscal year ending March 2026, revenue was 360,684 million yen (8.1% YoY increase), operating income was 148,739 million yen (15.1% YoY increase), and net income attributable to owners of parent for the quarter was 158,225 million yen (18.3% YoY increase). The consolidation of Torii Pharmaceutical as a subsidiary and the absorption-type split of JT\u2019s pharmaceutical business contributed to these results.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4507-20260130-02.pdf","jir_short_summary":"For the third quarter of the fiscal year ending March 2026, revenue was 360,684 million yen (8.1% YoY increase), operating income was 148,739 million yen (15.1% YoY increase), and net income attributable to owners of parent for the quarter was 158,225 million yen (18.3% YoY increase). The consolidation of Torii Pharmaceutical as a subsidiary and the absorption-type split of JT\u2019s pharmaceutical business contributed to these results.","jir_summary":"### Overview of Financial Results\nIn the cumulative consolidated period of the third quarter of the fiscal year ending March 2026, revenue amounted to 360,684 million yen (8.1% YoY increase), operating income to 148,739 million yen (15.1% YoY increase), and net income attributable to owners of parent for the quarter to 158,225 million yen (18.3% YoY increase). The consolidation of Torii Pharmaceutical Co., Ltd. as a subsidiary (September 1, 2025) and the absorption-type split of Japan Tobacco Inc.\u2019s pharmaceutical business (December 1, 2025) contributed to these results. Domestic prescription pharmaceuticals recorded 86.7 billion yen (9.8% YoY increase), overseas subsidiaries and exports were 48.9 billion yen (12.8% YoY increase), and royalty income was 201.3 billion yen (7.8% YoY increase). On the cost side, although selling, general and administrative expenses and research and development expenses increased, the recognition of a negative goodwill gain from the JT pharmaceutical business M&A pushed earnings higher.\n\n### Financial Position and Outlook\nAs of the end of the third quarter of the fiscal year ending March 2026, total consolidated assets were 1,727,987 million yen, an increase of 192,637 million yen compared to the previous fiscal year-end; total equity was 1,514,383 million yen, an increase of 151,886 million yen. Liabilities amounted to 213,603 million yen, increasing by 40,751 million yen. Cash flows from operating activities recorded an inflow of 123,524 million yen, investing activities recorded an outflow of 229,560 million yen, and financing activities recorded an outflow of 59,555 million yen, resulting in cash and cash equivalents of 215,595 million yen. There is no change to the full-year consolidated earnings forecast for the fiscal year ending March 2026, with projections of revenue at 500 billion yen (14.1% YoY increase), operating income at 185 billion yen (18.1% YoY increase), and net income attributable to owners of parent at 188 billion yen (10.3% YoY increase).","jir_financial_highlights":"Revenue: 360,684 million yen (8.1% YoY increase)\nOperating Income: 148,739 million yen (15.1% YoY increase)\nNet Income Attributable to Owners of Parent for the Quarter: 158,225 million yen (18.3% YoY increase)\nNumber of Shares Outstanding (Common Stock): 889,632,195 shares (Unknown)\nDividend Forecast (Annual): 66.00 yen (No revision from latest announced forecast)\nTotal Consolidated Assets: 1,727,987 million yen (Increase of 192,637 million yen from previous consolidated fiscal year-end)\nTotal Consolidated Equity: 1,514,383 million yen (Increase of 151,886 million yen from previous consolidated fiscal year-end)","jir_category":"","jir_hashtags":"#Shionogi, #FinancialSummary, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: 360,684 million yen (8.1% YoY increase)\nOperating Income: 148,739 million yen (15.1% YoY increase)\nNet Income Attributable to Owners of Parent for the Quarter: 158,225 million yen (18.3% YoY increase)","jir_meta_title":"Shionogi & Co., Ltd. Financial Summary for Q3 Fiscal Year Ending March 2026: Revenue Up 8.1%, Operating Income Up 15.1%","jir_meta_description":"Shionogi & Co., Ltd.'s financial summary for the third quarter of the fiscal year ending March 2026. Revenue of 360,684 million yen (8.1% YoY increase), operating income of 148,739 million yen (15.1% YoY increase), net income attributable to owners of parent of 158,225 million yen (18.3% YoY increase). Contributions from consolidation of Torii Pharmaceutical and absorption-type split of JT pharmaceutical business.","jir_og_title":"Shionogi & Co., Ltd. Announces Q3 Fiscal Year 2026 Financial Summary with Revenue and Profit Growth","jir_og_description":"Announced financial summary for Q3 of fiscal year ending March 2026. Revenue: 360,684 million yen, Operating Income: 148,739 million yen, Net Income: 158,225 million yen, with year-over-year increases.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year Trend of Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year March 2025\\\",\\\"Q3 Fiscal Year March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue (million yen)\\\",\\\"data\\\":[333600,360684],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year Trend of Operating Income\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year March 2025\\\",\\\"Q3 Fiscal Year March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income (million yen)\\\",\\\"data\\\":[129224,148739],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year Trend of Net Income Attributable to Owners of Parent for the Quarter\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 Fiscal Year March 2025\\\",\\\"Q3 Fiscal Year March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Net Income (million yen)\\\",\\\"data\\\":[133803,158225],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Revenue Breakdown for Q3 Fiscal Year Ending March 2026\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Domestic Prescription Pharmaceuticals\\\",\\\"Overseas Subsidiaries & Exports\\\",\\\"Royalty Income\\\"],\\\"datasets\\\":[{\\\"data\\\":[86700,48900,201300],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\"]}]}}\"}, {\"jir_chart_id\": \"capital_structure\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Trends of Total Equity and Total Liabilities\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"End of Fiscal Year March 2025\\\",\\\"End of Q3 Fiscal Year March 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Total Equity (million yen)\\\",\\\"data\\\":[1362497,1514383],\\\"backgroundColor\\\":\\\"#4e79a7\\\"},{\\\"label\\\":\\\"Total Liabilities (million yen)\\\",\\\"data\\\":[172852,213603],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-22162","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n